Skip to content

Study on the cough detection and analysis of pneumoconiosis patients based on Vivalink's wearable ECG patch

Study on the cough detection and analysis of pneumoconiosis patients based on Vivalink's wearable ECG patch

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075605
Enrollment
Unknown
Registered
2023-09-11
Start date
2023-09-11
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pneumoconiosis

Interventions

Gold Standard:The actual situation of the subjects during the experiment.
Index test:The subject wears a Vivalink's wearable ECG patch on the left front chest and uses the patch to collect chest surface vibration acceleration and ECG signals.

Sponsors

Shanghai Pulmonary Hospital, Tongji Univiersity
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients meeting the diagnostic criteria of pneumoconiosis; 2. Aged 18-80 years old, no restriction on gender; 3. No other respiratory or other systemic diseases that can cause cough detection abnormalities at the time of screening; 4. No significant cognitive impairment at the time of screening; 5. Good eyesight or hearing (glasses and hearing aids can be worn), able to cooperate with the investigator's instructions; 6. Not participating in other clinical trials.

Exclusion criteria

Exclusion criteria: 1. Patients with liver or kidney failure; 2. Patients with cardiac insufficiency; 3. Patients with multiple organ failure; 4. Patients with malignant tumors or undergoing anti-tumor treatment; 5. Patients with dyskinesia caused by heart, nervous system, bone and joint system diseases; 6. Female subjects of childbearing age during pregnancy and lactation; 7. Patients with cognitive impairment or mental problems who cannot cooperate with the trial; 8. Patients who are not eligible to participate in clinical trials according to the investigator, including those with existing physical or psychological conditions that preclude adherence to the protocol.

Design outcomes

Primary

MeasureTime frame
the chest surface vibration acceleration;Consistency between the chest surface vibration acceleration collected and the actual occurrence;

Secondary

MeasureTime frame
respiratory symptoms;

Countries

China

Contacts

Public ContactLing Mao

Department of Pneumoconiosis, Shanghai Pulmonary Hospital affiliated to Tongji University

drlingmao@163.com+86 139 1850 1570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026